ALLMedicine™ Achondroplasia Center
Research & Reviews 261 results
https://doi.org/10.1007/s40262-021-01059-1 10.1002/ajmg.a.40356 10.1136/adc.2010.189092 10.1002/humu.21636 10.1016/S0140-6736(07)61090-3 10.1111/cge.12045 10.1136/jmg.35.9.705 10.1097/DBP.0b013e3181c72052 10.1002/(SICI)1096-8628(19980616)78:1<30::AID-AJMG7>3.0.CO;2-P 10.1038/nrendo.2018.22 10.1007/s00431-017-2923-y 10.1515/JPEM.2001.14.1.17 10.1159/000446958 10.1016/j.jor.2015.01.001 10.1507/endocrj.K10E-164 10.1242/dev.105536 10.1073/pnas.071389098 10.1073/pnas.0407894101 10.1002/humu.20511 10.1152/ajpendo.00272.2009 10.1002/humu.20611 10.1124/jpet.114.218560 10.1210/en.2008-1676 10.1038/nm971 10.1242/jcs.02618 10.1016/j.ajhg.2012.10.014 10.1007/978-3-540-68964-5_15 10.1126/scitranslmed.aan4669 10.1111/j.1601-6343.2004.00308.x 10.1210/clinem/dgaa721 10.1056/NEJMoa1813446 10.1016/S0140-6736(20)31541-5 10.1208/s12248-014-9687-3 10.1007/s40262-013-0079-0 10.1111/j.1742-4658.2011.08082.x 10.1007/978-1-4614-6486-0_5 10.1016/j.biopha.2017.05.136 10.1208/s12248-012-9340-y 10.1111/apa.12266 10.1515/jpem-2020-0298 10.1093/ajcn/88.2.364 10.1002/ajmg.a.61272
Clinical Pharmacokinetics; Chan ML, Qi Y et. al.
Aug 26th, 2021 - Vosoritide, an analog of C-type natriuretic peptide, has been developed for the treatment of children with achondroplasia. The pharmacokinetics of vosoritide and relationships between plasma exposure and efficacy, biomarkers, and safety endpoints ...
https://doi.org/10.1242/dmm.048272
Disease Models & Mechanisms; Biosse Duplan M, Dambroise E et. al.
Aug 24th, 2021 - Achondroplasia (ACH), the most common form of dwarfism, is caused by a missense mutation in the gene coding for fibroblast growth factor receptor 3 (FGFR3). The resulting increase in FGFR3 signaling perturbs the proliferation and differentiation o...
https://doi.org/10.1080/09638288.2021.1963853
Disability and Rehabilitation; Constantinides C, Landis SH et. al.
Aug 18th, 2021 - Achondroplasia (ACH) is the most common form of skeletal dysplasia, resulting in disproportionate short stature and medical complications. We review the literature on physical functioning, psychosocial function, and quality of life (QoL) in ACH in...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344208
Orphanet Journal of Rare Diseases; Pfeiffer KM, Brod M et. al.
Aug 8th, 2021 - Currently, there is limited research on how having a child diagnosed with achondroplasia affects parents' lives. The purpose of the study was to investigate the experiences of parents of infants and young children less than two years of age with a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327889
Genetics in Medicine : Official Journal of the American C... Savarirayan R, Tofts L et. al.
Aug 4th, 2021 - Achondroplasia is caused by pathogenic variants in the fibroblast growth factor receptor 3 gene that lead to impaired endochondral ossification. Vosoritide, an analog of C-type natriuretic peptide, stimulates endochondral bone growth and is in dev...
News 9 results
https://www.medscape.com/viewarticle/939744
Oct 26th, 2020 - A year of daily subcutaneous vosoritide was associated with a 0.6-inch (1.5-cm) greater increase in height than placebo in children with achondroplasia, the most common form of human dwarfism. There was no difference in the incidence of side effec...
https://www.staging.medscape.com/viewarticle/939744
Oct 26th, 2020 - A year of daily subcutaneous vosoritide was associated with a 0.6-inch (1.5-cm) greater increase in height than placebo in children with achondroplasia, the most common form of human dwarfism. There was no difference in the incidence of side effec...
https://www.medscape.com/viewarticle/931243
May 29th, 2020 - (Reuters Health) - New clinical guidance from the American Academy of Pediatrics (AAP) on health supervision across the lifespan of people with achondroplasia focuses on recent advances in technology that can help diagnose and manage patients with...
https://www.medscape.com/viewarticle/914534
Jun 18th, 2019 - The results are preliminary, but a novel investigative agent has shown promise in a small trial in children for the treatment of achondroplasia, the most common form of human dwarfism. A phase 2 proof of concept study found that treatment with vos...
https://www.staging.medscape.com/viewarticle/914534
Jun 18th, 2019 - The results are preliminary, but a novel investigative agent has shown promise in a small trial in children for the treatment of achondroplasia, the most common form of human dwarfism. A phase 2 proof of concept study found that treatment with vos...
